QT
Quince Therapeutics, Inc.
SEC filingBiotechnology · South San Francisco, CA
Amount raised$114.7Msold at filing
Total offering$186.4M$71.7M still open
Investors in the raise27count reported to the SEC
FiledJun 11, 2026first sale May 18, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Dirk ThyeExecutive Officer, Director
June BrayDirector
Brendan HannahExecutive Officer
Brigette RobertsExecutive Officer, Director
Charles RyanExecutive Officer
Christopher SennerDirector
David LamondDirector
Executive officers, directors and promoters as listed on the Form D.